Press Detail

/
PRESS RELEASE

Biotest announces launch of BIVIGAM(TM)in the United States

Dreieich, February 4, 2013 - Biotest announces the launch of BIVIGAM(TM) in the US market. BIVIGAM(TM) is a human intravenous immune globulin 10% liquid, which will be distributed by Biotest Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest AG. The product is now available on a regular basis for patients with Primary Humoral Immunodeficiency (PID).

To best serve the U.S.market, Biotest has made significant investments in its infrastructure and its ability to efficiently manufacture and deliver the product. In addition to a greater than $50 million investment to enhance the capacity of its state-of-the-art Boca Raton, Florida protein purification facility, Biotest also has developed and deployed a comprehensive logistics operation to better serve its customers.

'The U.S. Food and Drug Administration's (FDA) approval and first launch of BIVIGAM are key corporate milestones for Biotest. The expansion and enhancement of our manufacturing capabilities have positioned us strongly to meet current and future patient and market demand,' said Jordan Siegel, Chief Executive Officer of BPC. 'We are committed to supporting PID patients with BIVIGAM(TM) to ensure their uncompromised living.'

BIVIGAM(TM) is a sugar-free, glycine stabilized intravenous immune globulin that was approved by the FDA December 19th, 2012. For additional services, please visit www.BIVIGAM.com.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart